Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06799247 · ClinicalTrials.gov registry record · Phase 3
Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis
A Phase 3 study of Myasthaenia Gravis, sponsored by Cartesian Therapeutics.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 100
- Enrollment target
- 20
- Study locations
NCT06799247: Recruiting Phase 3 study of Myasthaenia Gravis, sponsored by Cartesian Therapeutics.
NCT06799247 is a Phase 3 study of Myasthaenia Gravis that is actively recruiting participants, run by Cartesian Therapeutics. The registered enrollment target is 100 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (87% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06799247, a Phase 3 study of Myasthaenia Gravis, is actively recruiting participants, sponsored by Cartesian Therapeutics.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 100 participants
- Enrollment target
- 20
- Study locations
Study Summary
The AURORA Study is evaluating the safety, tolerability, and efficacy of an investigational mRNA CAR T-cell therapy known as Descartes-08 in adults with acetylcholine receptor autoantibody -positive generalized myasthenia gravis. Part 1 of the study will last around 6 months. For eligible participants, Part 2 will last around 8 months.
Primary Outcome
To evaluate the efficacy of Descartes-08 as assessed by the proportion of Myasthenia Gravis Activities of Daily Living (MG-ADL) responders at Month 4.
Conditions Studied
Interventions
- BIOLOGICAL Decartes-08
- OTHER Placebo Drug
Study Locations (20)
California
- A13 - Carlsbad
- A14 - Orange
Florida
- A48 - Maitland
- A10 - Tampa
New York
- A12 - Amherst
- A47 - New York
North Carolina
- A22 - Chapel Hill
- A39 - Charlotte
Pennsylvania
- A11 - Philadelphia
- A49 - Pittsburgh
Other
- A23 - Rome
- A30 - Krakow
Arizona
- A40 - Tucson
Colorado
- A21 - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2025-05-06 |
| Est. Completion | 2027-09-30 |
| Phase | Phase 3 |
What NCT06799247 shows while recruiting
NCT06799247 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Myasthaenia Gravis appearing as the primary indexed condition, and to 2 interventions - of which Decartes-08 is the first listed.
NCT06799247 names 20 study sites across 14 states, led by California, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT06799247 about?
NCT06799247 is a clinical study titled "Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis". The AURORA Study is evaluating the safety, tolerability, and efficacy of an investigational mRNA CAR T-cell therapy known as Descartes-08 in adults with acetylcholine receptor autoantibody -positive generalized myasthenia gravis. Part 1 of the study will last around 6 months. For eligible participan...
What is the current status of trial NCT06799247?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 100 participants. The study started on 2025-05-06. Estimated completion is 2027-09-30.
What conditions does trial NCT06799247 study?
This clinical trial studies the following conditions: Myasthaenia Gravis.
What interventions are being tested in trial NCT06799247?
The interventions under investigation include: Decartes-08 (BIOLOGICAL), Placebo Drug (OTHER).
Who is sponsoring clinical trial NCT06799247?
This trial is sponsored by Cartesian Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06799247 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myasthaenia Gravis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06799247's enrollment target sits among peer trials
100 1682nd of 2000 higher than 288 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI